|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCNN1G |
Gene summary for SCNN1G |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCNN1G | Gene ID | 6340 |
| Gene name | sodium channel epithelial 1 subunit gamma | |
| Gene Alias | BESC3 | |
| Cytomap | 16p12.2 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A5X2V1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6340 | SCNN1G | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 7.98e-08 | 5.43e-01 | 0.1621 |
| 6340 | SCNN1G | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 4.93e-04 | 5.53e-01 | 0.1622 |
| 6340 | SCNN1G | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.29e-02 | 2.87e-01 | 0.1575 |
| 6340 | SCNN1G | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 3.36e-02 | 3.10e-01 | 0.1545 |
| 6340 | SCNN1G | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 5.57e-03 | 3.36e-01 | 0.1569 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004854519 | Prostate | Tumor | response to steroid hormone | 118/3246 | 339/18723 | 4.46e-15 | 6.94e-13 | 118 |
| GO:007138317 | Prostate | Tumor | cellular response to steroid hormone stimulus | 76/3246 | 204/18723 | 7.73e-12 | 6.16e-10 | 76 |
| GO:190165418 | Prostate | Tumor | response to ketone | 70/3246 | 194/18723 | 2.69e-10 | 1.48e-08 | 70 |
| GO:003196017 | Prostate | Tumor | response to corticosteroid | 57/3246 | 167/18723 | 1.11e-07 | 2.94e-06 | 57 |
| GO:007138414 | Prostate | Tumor | cellular response to corticosteroid stimulus | 26/3246 | 61/18723 | 3.31e-06 | 5.41e-05 | 26 |
| GO:190165512 | Prostate | Tumor | cellular response to ketone | 33/3246 | 96/18723 | 4.19e-05 | 4.76e-04 | 33 |
| GO:009730518 | Prostate | Tumor | response to alcohol | 68/3246 | 253/18723 | 9.02e-05 | 8.88e-04 | 68 |
| GO:005138513 | Prostate | Tumor | response to mineralocorticoid | 15/3246 | 36/18723 | 5.27e-04 | 3.85e-03 | 15 |
| GO:005087818 | Prostate | Tumor | regulation of body fluid levels | 91/3246 | 379/18723 | 5.37e-04 | 3.91e-03 | 91 |
| GO:009730611 | Prostate | Tumor | cellular response to alcohol | 27/3246 | 93/18723 | 3.59e-03 | 1.85e-02 | 27 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCNN1G | SNV | Missense_Mutation | rs550929094 | c.1319G>A | p.Arg440Gln | p.R440Q | P51170 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SCNN1G | SNV | Missense_Mutation | novel | c.1271A>G | p.Asn424Ser | p.N424S | P51170 | protein_coding | tolerated(0.05) | probably_damaging(0.998) | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
| SCNN1G | SNV | Missense_Mutation | rs150854967 | c.1891N>T | p.Arg631Cys | p.R631C | P51170 | protein_coding | deleterious(0) | possibly_damaging(0.609) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SCNN1G | SNV | Missense_Mutation | rs267604464 | c.413N>A | p.Arg138Gln | p.R138Q | P51170 | protein_coding | tolerated(0.23) | probably_damaging(0.998) | TCGA-D8-A27I-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimycin+cyclophosphamide | SD |
| SCNN1G | SNV | Missense_Mutation | c.139T>A | p.Ser47Thr | p.S47T | P51170 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| SCNN1G | insertion | Frame_Shift_Ins | novel | c.978_979insGAAGTAG | p.Ala327GlufsTer4 | p.A327Efs*4 | P51170 | protein_coding | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| SCNN1G | insertion | In_Frame_Ins | novel | c.980_981insAGGGCTGTATCATCATCACCTTGA | p.Ala327_Lys328insGlyLeuTyrHisHisHisLeuAsp | p.A327_K328insGLYHHHLD | P51170 | protein_coding | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| SCNN1G | insertion | In_Frame_Ins | novel | c.1272_1273insCCCAGCTCAGCCCCATCTCCATATCTCAGT | p.Asn424_Tyr425insProSerSerAlaProSerProTyrLeuSer | p.N424_Y425insPSSAPSPYLS | P51170 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| SCNN1G | deletion | Frame_Shift_Del | novel | c.1607delG | p.Gly536AlafsTer4 | p.G536Afs*4 | P51170 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SCNN1G | SNV | Missense_Mutation | c.1429N>A | p.Glu477Lys | p.E477K | P51170 | protein_coding | tolerated(0.07) | possibly_damaging(0.847) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | amiloride | AMILORIDE | 23788015 | |
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | P-552 | |||
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | TRIAMTERENE | TRIAMTERENE | ||
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | AMILORIDE | AMILORIDE | ||
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | blocker | CHEMBL1398126 | AMILORIDE HYDROCHLORIDE | |
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | AMILORIDE | AMILORIDE | ||
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GS-9411 | |||
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | TRIAMTERENE | TRIAMTERENE | ||
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | blocker | CHEMBL585 | TRIAMTERENE | |
| 6340 | SCNN1G | ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | triamterene | TRIAMTERENE | 23788015 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |